Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : WR's Momentum Trades -- Ignore unavailable to you. Want to Upgrade?

To: Wayne Rumball who wrote (1600)	12/23/1998 12:34:00 PM
From: DR. MEADE	Respond to of 11130

Wednesday December 23, 10:00 am Eastern Time Company Press Release SOURCE: Advanced Plant Pharmaceuticals Inc. Advanced Plant Pharmaceuticals Inc. Announces Exclusive Distribution Agreement for Patented Cholesterol Lowering Agent Lo-Chol and New Line of Proprietary Whole Plant Standardized Pharmaceutical Grade Products NEW YORK, Dec. 23 /PRNewswire/ -- Advanced Plant Pharmaceuticals Inc. (OTC Bulletin Board: APPI - news) announced today that they have signed an agreement with Klien Associates of Israel. The provisions of the agreement call for the exclusive distribution of Lo-Chol and APPI's new product line of various Pharmaceutical Grade Nutritional products by Klien Associates throughout the Country of Israel. Pursuant to the agreement Klien Associates has made an initial purchase order of Lo-Chol and will have an exclusive 3 month trial distribution right to distribute Lo-Chol in the territory of Israel. Upon the completion of the trial distribution period Klien Associates will have the right of first refusal for the distribution of Lo-Chol and APPI's new line of various Pharmaceutical Grade Nutritional products exclusively in Israel based on minimum purchases and conditions that will be set forth in a new agreement. The company expects to announce further agreements in the near future. APPI is a company that develops innovative plant formulations and technology for clinical application. APPI has met FDA nutritional specifications for the marketing of its Lo-Chol in the USA, and has received the first IND from the FDA for a whole plant pharmaceutical which has potential as an immunomodulater in the treatment of patients infected with HIV, the virus that causes AIDS. APPI's Whole Plant Pharmaceutical Grade Process is trade secret and patent pending. Utilization of the APPI process converts a whole plant into the best standardized pharmaceutical grade product. This press release contains forward-looking statements. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. SOURCE: Advanced Plant Pharmaceuticals Inc. ------------------------------------------------------------------------ More Quotes and News:Advanced Plant Pharmaceuticals Inc (OTC BB:APPI - news)Related News Categories: medical/pharmaceutical ------------------------------------------------------------------------ Help ------------------------------------------------------------------------ Copyright © 1998 PRNewswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

To: Wayne Rumball who wrote (1600)	12/23/1998 12:36:00 PM
From: Shoot1st	Read Replies (1) \| Respond to of 11130

Was in APPI a year ago..think I bought at .19.......nevermore....bawwwk! SS1